Domantis has raised $29 million in new venture funds. New investors Novo Nordisk and MC Life Science Ventures--a subsidiary of Mitsubishi Corporation--led the round. "Domantis' twelve lead programs are based on novel dAb products for treating major diseases including COPD, rheumatoid arthritis, asthma and colorectal cancer," said Domantis CEO Robert Connelly. "This financing, together with the growing revenue stream from our nine partnerships, provides sufficient resources to fund the clinical development of these programs." Domantis is based in Waltham, MA and the UK.
- read this release for more information